This is particularly meaningful from a research perspective, as elevated triglycerides represent an independent cardiovascular risk factor that is often undertreated by GLP-1 class compounds alone
O.OhanadorR.OmoregieE
[2] Additionally, GLP-1 agonists have been shown to reduce markers of systemic inflammation, including C-reactive protein (CRP), in patients with type 2 diabetes and cardiovascular disease, though these reductions are often modest
GLP-1 activation led to decreased production of inflammatory cytokines
However, Partnership for Safe Medicines Executive Director Shabbir Imber Safdar stated that these votes are a serious setback for patient safety," adding that the Pharmaceutical Compounding Advisory Committee voted to advance substances that FDAs own scientists flagged as lacking adequate evidence of safety, efficacy, or quality
[16] Chitapanarux I, Chitapanarux T, Traisathit P, et al